Expertise and infrastructure related to HIV surveillance, clinical trials and molecular diagnostics allowed BHP to be in a unique position to rapidly respond to the COVID-19 pandemic.  BHP partnered with the government to stand up robust SARS CoV2 PCR testing within days of the first diagnosed cases (performing more than 1/3 of testing for the country).  Additionally, the BHP lab created a world-class program for SARS CoV2 genomic surveillance using molecular sequencing which led to the discovery of the omicron variant [ht

From ground-breaking clinical trials to observational cohorts and epidemiologic surveillance, BHP has remained a global leader in maternal and pediatric HIV research since early in the HIV epidedmic, with BHP findings leading to global guidelines changes.  The focus of the research has always been to find ways to improve the health outcomes of pregnant women living with HIV and their children.

The BHP research laboratory has over the years played a critical role in carrying out molecular virology work on HIV and this has built capacity that has enabled work on other pathogens including Hepatitis B virus(HBV), Mycobactrerium tuberculosis (M.Tb), Human Papillomavirus (HPV) and more recently SARS-CoV-2. The overarching aim of the lab is to use genomic data to understand phenotypic and clinical impact of genomic variation.

The BHP Clinical Trials Unit (CTU) has conducted multiple international clinical trials, under the AID Clinical Trials Group (ACTG) and and other related networks, which are high impact and aimed to improve the treatment of HIV and its co-infections, including TB, viral hepatitis and other co-morbidities and seeking to advance approaches to cure HIV.

BHP has conducted studies focused on cancer in Botswana since around 2010.

BHP investigators lead a group of studies to evaluate and address untreated hypertension in Botswana, as this is a major risk factor for cardiovascular disease (including stroke) in the region. Investigators are also evaluating the prevalence and manifestations of frailty, particularly in older persons with and without HIV.

The global epidemics of depression and anxiety also affect impact Africa. BHP investigators are evaluating rates of peripartum depression, and piloting locally feasible approaches to diagnosing and treatment.

Sociobehavioural research is essential, for understanding how to offer the treatments and other interventions that we know are efficacioous and safe.  BHP investigators lead qualitative research focused on areas such as HIV stigma and HIV self-testing.

HIV prevention research, primarily through biomedical means, has been a significant area of focus for BHP.

Botswana is vulnerable to climate change and its impact. BHP investigators are starting to evaluate the impact of climate change on human health--for example, demonstrating that adverse birth outcomes vary by season in Botswana (https://bmjopen.bmj.com/content/11/9/e045882).